NKF KDOQI GUIDELINES

KDOQI (Kidney Disease Outcomes Quality Initiative)

Published KDOQI Guidelines Are Available Online – click here.
www.kdoqi.org

KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease

FIGURES

Figure 1.	Percentage of Patients in Each Group of the Steno Study Who Reached the Intensive-Treatment Goals at a Mean of 7.8 Years.
Figure 2.	Annual Transition Rates with 95% Confidence Intervals Through the Stages of Nephropathy and to Death from any Cause.
Figure 3.	CVD Outcomes by Treatment Assignment in DCCT/EDIC.
Figure 4.	Diabetes Amplifies the CKD and CVD Paradigm.
Figure 5.	Cumulative Incidence Estimate of the Combined Primary End Point for Placebo and Atorvastatin Treatment Groups in the 4D.
Figure 6.	Screening for Microalbuminuria.
Figure 7.	Receiver Operator Characteristic (ROC) Curve of the Probability that the Presence of Diabetic Retinopathy is Predictive of Patients who have Biopsy/Histology-Proven Diabetic Glomerulopathy.
Figure 8.	Cumulative Incidence of Urinary Albumin Excretion of 300 mg/24 h or Greater and 40 mg/24 h or Greater in Patients with Type 1 Diabetes Mellitus Receiving Intensive or Conventional Therapy.
Figure 9.	Prevalence and Cumulative Incidence of Microalbuminuria.
Figure 10.	Cumulative Incidence of DKD After 6 Years of Follow-up in Patients with Type 2 Diabetes Treated by Intensive and Conventional Insulin Injection Therapy in the Primary-Prevention Cohort of the Kumamoto Study.
Figure 11.	Cumulative Incidence of DKD After 8 Years of Follow-up in Patients with Type 2 Diabetes Treated by Intensive and Conventional Insulin Injection Therapy in the Primary-Prevention Cohort of the Kumamoto Study.
Figure 12.	Prevalence and Incidence of Albuminuria.
Figure 13.	Results from the CSG Captopril Trial.
Figure 14.	Results from the IDNT.
Figure 15.	Reduction of End Points in Type 2 Diabetes with Losartan in RENAAL.
Figure 16.	Systematic Review of Studies of DKD and Non-DKD.
Figure 17.	Meta-Analysis of Studies of DKD and Non-DKD.
Figure 18.	Blood Pressure Level and Rate of GFR Decline in Controlled Trials of DKD.
Figure 19.	Effect of Pravastatin on the Absolute Risk Reduction (ARR) of Fatal Coronary Disease, Nonfatal Myocardial Infarction, or Coronary Revascularization by CKD and Diabetes (DM) Status.
Figure 20.	Median Change in LDL-C Concentrations From Baseline Until the End of the 4D.
Figure 21.	Meta-Analysis Demonstrating Reduced Risk of Progression of DKD (Loss of Kidney Function or Increased Albuminuria) by Treatment with Low-Protein Diets.
Figure 22.	Effect of Reduced Dietary Protein Intake on CKD Stage 5 and Death in Type 1 Diabetes and CKD Stage 2 (inferred) at baseline.
Figure 23.	Hazard Ratios for CVD and Heart Failure End Points as a Function of Percent Change in 6-month Albuminuria in the RENAAL Trial.
Figure 24.	Hazard Ratios for Kidney End Points (Doubling of Serum Creatinine, CKD Stage 5, or Death) and CKD Stage 5 as a Function of Percent Change in 6-month Albuminuria in the RENAAL Trial.
Figure 25.	Kaplan-Meier Analysis of Kidney End Points (Doubling of Serum Creatinine [SCr], SCr Level > 6 mg/dL, or CKD Stage 5) by Level of Proteinuria Change in the First 12 Months of IDNT.
Figure 26.	Reduction of End Points with Intensive Multifactorial Therapy in the Steno 2 Study.
Figure 27.	Estimated Number of Adults with Diabetes by Age Group and Year for the Developed and Developing Countries and for the World.
Figure 28.	Adjusted Incident Rates of CKD Stage 5 Due to Diabetes by Race/Ethnicity.